Transgender Males on Gender-Affirming Hormone Therapy and Hepatobiliary Neoplasms: A Systematic Review
Authors' conclusion
Results of this review are not sufficient to conclude that there is an association between GAHT and hepatobiliary neoplasms. This supports current evaluation and screening guidelines for initiation and continuation of GAHT in transgender men. The heterogeneity of testosterone formulations limits the translation of risks of hepatobiliary neoplasms in other indications to GAHT.
Study context
- Population
- Cases of hepatobiliary neoplasm in patients with exogenous testosterone administration or endogenous overproduction, across indications; non-English articles excluded49 papers
- Participants
- 62 cases
- Outcome
- Hepatocellular adenoma, hepatocellular carcinoma, cholangiocarcinoma or other biliary neoplasm with testosterone administration or endogenous overproduction
Methodological details1273 unique citations screened from Ovid Medline, Embase.com, Scopus, Cochrane Database of Systematic Reviews and clinicaltrials.gov
- 1273 unique citations screened from Ovid Medline, Embase.com, Scopus, Cochrane Database of Systematic Reviews and clinicaltrials.gov
Pooled result
As reported in the abstract
Papers with cases
49
Unique cases
62
Original publication
Transgender Males on Gender-Affirming Hormone Therapy and Hepatobiliary Neoplasms: A Systematic Review. Endocr Pract. Published 5 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →